The safety profile and the statistically significant efficacy in patients receiving ATX-101 strongly support expansion of our product development efforts,” said Patricia Walker, MD, PhD, KYTHERA's Chief Medical Officer. In both studies, ATX -101 was well tolerated. In the rapidly growing market of minimally-invasive, non-surgical facial rejuvenation, the reduction of facial fat deposits to restore and reshape the jawline remains one of the largest unmet patient needs.
Hydralazine can cause fluid retention and therefore should be combined with a diuretic. SLE like syndrome can occur when used in large doses. Minoxidil causes increased facial hair and is therefore unsuitable for female patients. 
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment